ZhuZhou QianJin Pharmaceutical Co Ltd
SSE:600479
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (10), the stock would be worth ¥11.63 (6% upside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 9.4 | ¥11.01 |
0%
|
| 3-Year Average | 10 | ¥11.63 |
+6%
|
| 5-Year Average | 9.1 | ¥10.68 |
-3%
|
| Industry Average | 30.7 | ¥35.85 |
+226%
|
| Country Average | 28.8 | ¥33.63 |
+205%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
ZhuZhou QianJin Pharmaceutical Co Ltd
SSE:600479
|
5.4B CNY | 9.4 | 21.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 157.8 | 44 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 29.2 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 39.6 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 19.6 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 25.2 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 45.7 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 21.9 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 11.7 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 14.5 |
| Median | 28.8 |
| 70th Percentile | 57 |
| Max | 307 555.7 |
Other Multiples
ZhuZhou QianJin Pharmaceutical Co Ltd
Glance View
Zhuzhou Qianjin Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceutical products. The company is headquartered in Zhuzhou, Hunan and currently employs 4,975 full-time employees. The company went IPO on 2004-03-12. The firm's main products include tablets, granules, pills, hard capsules, syrups, herbs, vinum and gels, among others. The firm is also involved in the businesses of cultural entertainment, logistics and distribution, as well as the provision of hygienic products.
